BIO vs PEN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 21, 2026

BIO

37.1
AI Score
VS
PEN Wins

PEN

49.9
AI Score

Investment Advisor Scores

BIO

37score
Recommendation
SELL

PEN

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BIO PEN Winner
Revenue 1.24B 764.80M BIO
Net Income -155.70M 67.39M PEN
Gross Margin 52.7% 67.8% PEN
Net Margin -12.5% 8.8% PEN
Operating Income 106.70M 79.27M BIO
ROE -2.2% 4.4% PEN
ROA -1.5% 3.4% PEN
Total Assets 10.25B 1.97B BIO
Cash 517.00M 205.27M BIO
Current Ratio 3.14 5.75 PEN
Free Cash Flow 144.80M 105.84M BIO

Relative Price Performance (Last 90 Days)

BIO 1M: +20.1% · 3M: +32.5% PEN 1M: +2.3% · 3M: -0.8%

Current Technical Phase

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.9% over 20 days), RSI 78

RSI (14): 78.2 · Price: $380.03

PEN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 56.3 · Price: $325.18

Fundamentals Snapshot

Metric BIO PEN
Market Cap
Forward P/E 37.9 52.8
Trailing P/E 44.4 79.9
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin 0.5% 0.7%
Operating Margin 0.1% 0.1%
EPS 8.47 4.09
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PEN is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.